Ignite Creation Date:
2024-05-05 @ 10:17 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002558
Status:
COMPLETED
Last Update Posted:
2016-05-23
First Post:
1999-11-01
Brief Title:
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
PHASE III TRIAL OF SEQUENTIAL TAXOLIFOSFAMIDE AND DOSEINTENSIVE CARBOPLATINETOPOSIDE WITH STEM CELL SUPPORT IN CISPLATIN-RESISTANT GERM CELL TUMOR PATIENTS WITH UNFAVORABLE PROGNOSTIC FEATURES
Status:
COMPLETED
Status Verified Date:
2016-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy such as paclitaxel ifosfamide carboplatin and etoposide work in different ways to stop the growth of tumor cells either by killing them or by stopping them from dividing Giving chemotherapy with a peripheral stem cell transplant may allow more chemotherapy to be given so that more tumor cells are killed
The design of this trial is a phase III trial of sequential accelerated chemotherapy cycles with taxolifosfamide and carboplatinetoposide administered with G-CSF and PBSC support
PURPOSE The purpose of this study is to determine the effects of an intensive sequence of chemotherapy drugs in patients with metastatic germ cell cancer All of these chemotherapy drugs are known to be active in this disease
The design of this trial is a phase III trial of sequential accelerated chemotherapy cycles with taxolifosfamide and carboplatinetoposide administered with G-CSF and PBSC support
PURPOSE The purpose of this study is to determine the effects of an intensive sequence of chemotherapy drugs in patients with metastatic germ cell cancer All of these chemotherapy drugs are known to be active in this disease
Detailed Description:
OBJECTIVES
Determine the safety of paclitaxel and ifosfamide followed by carboplatin and etoposide with stem cell support in patients with unfavorable germ cell tumors with unfavorable prognostic factors and resistance to cisplatin
Determine the efficacy of this regimen as salvage therapy in these patients
Escalate the dose of carboplatin based on a target area under the concentration time curve and renal function and determine the pharmacokinetics of carboplatin in selected patients
Determine the qualitative effects of paclitaxel and ifosfamide on hematopoietic progenitors in these patients
OUTLINE This is a dose escalation study of carboplatin
Part A Patients receive paclitaxel IV continuously on day 1 and ifosfamide IV over 4 hours on days 2-4 Autologous peripheral blood stem cells PBSC are harvested on days 11-13 Filgrastim G-CSF is administered subcutaneously SC twice daily beginning 6 hours after completion of paclitaxel and ifosfamide infusions and continuing until the last day of leukapheresis Treatment continues every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity Before beginning the first course of chemotherapy autologous bone marrow ABM is harvested if possible in case insufficient peripheral blood stem cells PBSC are harvested Patients who were unable to undergo harvest of ABM before the first course of chemotherapy undergo harvest of ABM before beginning the second course of chemotherapy
Part B Beginning 2 weeks after completion of regimen A patients receive etoposide IV over 2 hours and carboplatin IV over 1 hour on days 1-3 PBSC are reinfused on day 5 G-CSF is administered SC twice daily beginning 6 hours after completion of etoposide and carboplatin infusions and continuing until blood counts recover G-CSF is held on the morning of PBSC transplantation and restarted beginning 6 hours after completion of PBSC transplantation Treatment continues every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity Patients with insufficient PBSC for the second course receive PBSC combined with ABM Patients with insufficient PBSC for the third course receive ABM
During the second part cohorts of 3-6 patients receive escalating doses of carboplatin until the maximum tolerated dose MTD is determined The MTD is defined as the dose preceding that at which 3 of 6 patients experience dose-limiting toxicity
After completion of parts A and B some patients may undergo resection of residual masses
Determine the safety of paclitaxel and ifosfamide followed by carboplatin and etoposide with stem cell support in patients with unfavorable germ cell tumors with unfavorable prognostic factors and resistance to cisplatin
Determine the efficacy of this regimen as salvage therapy in these patients
Escalate the dose of carboplatin based on a target area under the concentration time curve and renal function and determine the pharmacokinetics of carboplatin in selected patients
Determine the qualitative effects of paclitaxel and ifosfamide on hematopoietic progenitors in these patients
OUTLINE This is a dose escalation study of carboplatin
Part A Patients receive paclitaxel IV continuously on day 1 and ifosfamide IV over 4 hours on days 2-4 Autologous peripheral blood stem cells PBSC are harvested on days 11-13 Filgrastim G-CSF is administered subcutaneously SC twice daily beginning 6 hours after completion of paclitaxel and ifosfamide infusions and continuing until the last day of leukapheresis Treatment continues every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity Before beginning the first course of chemotherapy autologous bone marrow ABM is harvested if possible in case insufficient peripheral blood stem cells PBSC are harvested Patients who were unable to undergo harvest of ABM before the first course of chemotherapy undergo harvest of ABM before beginning the second course of chemotherapy
Part B Beginning 2 weeks after completion of regimen A patients receive etoposide IV over 2 hours and carboplatin IV over 1 hour on days 1-3 PBSC are reinfused on day 5 G-CSF is administered SC twice daily beginning 6 hours after completion of etoposide and carboplatin infusions and continuing until blood counts recover G-CSF is held on the morning of PBSC transplantation and restarted beginning 6 hours after completion of PBSC transplantation Treatment continues every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity Patients with insufficient PBSC for the second course receive PBSC combined with ABM Patients with insufficient PBSC for the third course receive ABM
During the second part cohorts of 3-6 patients receive escalating doses of carboplatin until the maximum tolerated dose MTD is determined The MTD is defined as the dose preceding that at which 3 of 6 patients experience dose-limiting toxicity
After completion of parts A and B some patients may undergo resection of residual masses
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-V94-0407 | US NIH GrantContract | None | httpsreporternihgovquickSearchP30CA008748 |
| P30CA008748 | NIH | None | None |
| MSKCC-93162 | None | None | None |